The 5 April 2024 Announcement
POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV (BIT225-010)
Stated That:
The double-blind placebo-controlled Phase 2 trial
was designed to characterise the effect of BIT225 (200 mg, once daily for 24 weeks)
added to a standard of care antiretroviral therapy cART:
50 mg Dolutegravir (DTG),
300 mg Tenofovir disproxil fumarate (TDF) and
200 mg Emtricitabine (FTC)
So the question may be who makes the cART drugs?
Dolutegravir (DTG), is owned by Viiv Healthcare (majority-owned by GSK, with Pfizer Inc)
Tenofovir disproxil fumarate (TDF) is owned by Gilead
Emtricitabine (FTC) is owned by Gilead
That perhaps may give some indication of who potential partners could be....![]()
- Forums
- ASX - By Stock
- Ann: POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV
The 5 April 2024 Announcement POSITIVE OUTCOMES IN BIT225 PHASE...
-
- There are more pages in this discussion • 100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
2.6¢ |
Change
-0.001(3.70%) |
Mkt cap ! $23.46M |
Open | High | Low | Value | Volume |
2.7¢ | 2.7¢ | 2.6¢ | $8.415K | 322.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 37530 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.026 |
7 | 804946 | 0.025 |
2 | 3453333 | 0.024 |
1 | 130000 | 0.023 |
4 | 825000 | 0.022 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 37530 | 1 |
0.028 | 145600 | 2 |
0.029 | 260000 | 2 |
0.030 | 49844 | 3 |
0.031 | 280868 | 5 |
Last trade - 15.23pm 16/08/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |